• Research and Demonstration Projects: Peru hosted three sites in the phase III iPrEx trial, and the open-label extension of iPrEx. Several studies have shown the cost-effectiveness of rolling out PrEP in Peru, as well as looked at delivery issues such as provider attitudes and acceptability.
  • Drug Registration: Truvada is registered for treatment. In April 2016 the Peru Ministry of Health approved the use of fixed-dose combination of tenofovir disoproxyl fumarate and emtricitabine for PrEP.
  • Policy/Regulatory: There is no national PrEP policy or guidance at present.
  • Advocacy: Peruvian NGOs, such as Epicentro and Investigaciones Médicas en Salud (Inmensa), have worked on PrEP research and advocacy.

Last updated on September 1, 2017.

News Spotlight